AIM Shares: 1 biotech stock to watch in 2021

Investing in AIM Shares can be risky, but they can also offer large returns. Zaven Boyrazian looks at one biotech stock driving drug development.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

Biotech stocks have been at the centre of the Covid-19 vaccine development effort. So it’s no surprise that their share prices have generally been on fire lately. There are lots of AIM shares operating in this industry. But one, in particular, has caught my attention. Could this biotech stock be my next investment? Let’s take a look.

Using biotech to diagnose Covid-19

Abcam (LSE:ABC) manufactures pharmaceutical reagents and provides research tools to companies engaged in diagnostics and drug development. Over the years, the firm has built up a vast portfolio of over 450 antibodies that are commonly used in blood tests (including those used to diagnose Covid-19) as well as the development of new medicines.

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

I discovered an impressive figure from 2019. Almost half of the scientific papers published related to drug development cited one of Abcam’s products as critical to the research. Needless to say, the firm’s products are well known and widely used. And they have even led to 20 new treatments that are either FDA approved or in clinical trials today.

The business generates revenue from several sources. The bulk comes from the direct selling of reagents to customers worldwide. The other — currently much smaller — sources include service fees, licenses of its technology, and royalties from approved treatments.

The latter component is what I find most fascinating as Abcam continues to receive a portion of each sale of a treatment that was developed using its reagents. Due to the typical 10-year drug development cycle, the number of FDA approved medicines using Abcam’s products is currently quite low. But over the long term, I expect this revenue source to become far more substantial.

The biotech stock is not risk-free

Beyond its shares being AIM-listed, Abcam is exposed to multiple risks. Its international operations did help make it a globally recognised brand within the biotech industry. But as a result, most of the revenue now originates from outside the UK, primarily coming from North America. This exposes the firm to fluctuating currency rates that may have a notable impact on the bottom line.

This global presence also introduces some additional complications regarding regulatory compliance. As I’ve previously discussed, the pharmaceutical industry has some of the world’s strictest regulations. Different countries have different regulatory standards. And while most are similar to FDA, there are some differences that Abcam needs to comply with.

If the business fails to do so, its products would no longer be allowed to be used in certain countries. And it would likely have a significant impact on the business from both a legal and reputational standpoint.

There are risks in investing in AIM Shares even for this biotech stock

The bottom line: should I buy shares in this AIM Stock

Despite the impressive and vital technology that Abcam provides, it’s not a stock I’ll be adding to my portfolio. At least not at the current price.

The firm’s net income has recently been dropping as it has begun increasing spending to expand faster. Sacrificing profits in the name of growth is a perfectly acceptable strategy, in my opinion. However, this promise of growth has elevated the share price to a level that seems unsustainable to me.

With a P/E ratio of nearly 280, Abcam just looks too expensive. But I’ll be keeping a close eye on it for any potential buying opportunities throughout 2021.

Abcam may not be my next investment, but there is another stock I've found that looks promising. Here is:

The high-calibre small-cap stock flying under the City’s radar

Adventurous investors like you won’t want to miss out on what could be a truly astonishing opportunity…

You see, over the past three years, this AIM-listed company has been quietly powering ahead… rewarding its shareholders with generous share price growth thanks to a carefully orchestrated ‘buy and build’ strategy.

And with a first-class management team at the helm, a proven, well-executed business model, plus market-leading positions in high-margin, niche products… our analysts believe there’s still plenty more potential growth in the pipeline.

Here’s your chance to discover exactly what has got our Motley Fool UK investment team all hot-under-the-collar about this tiny £350+ million enterprise… inside a specially prepared free investment report.

But here’s the really exciting part… right now, we believe many UK investors have quite simply never heard of this company before!

Click here to claim your copy of this special investment report — and we’ll tell you the name of this Top Small-Cap Stock… free of charge!

Zaven Boyrazian does not own shares in Abcam. The Motley Fool UK has recommended Abcam. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

macro shot of computer monitor with FTSE 100 stock market data in trading application
Investing Articles

Here’s a FTSE 250 stock to buy to benefit from the construction boom!

Jabran Khan details a FTSE 250 stock that could be primed to benefit from the infrastructure and construction boom.

Read more »

Young woman working at modern office. Technical price graph and indicator, red and green candlestick chart and stock trading computer screen background.
Investing Articles

Is the Royal Mail share price a buying opportunity?

With a 6% dividend yield and a price-to-earnings ratio of 3, is the Royal Mail share price in buying territory?…

Read more »

Scene depicting the City of London, home of the FTSE 100
Investing Articles

3 FTSE 100 shares! Should I buy them?

I'm searching for the best FTSE 100 stocks to buy following recent market volatility. Are these blue-chip UK shares too…

Read more »

macro shot of computer monitor with FTSE 100 stock market data in trading application
Investing Articles

Should I buy one of the cheapest shares on the FTSE 100 index?

This Fool explores one of the cheapest stocks on the FTSE 100 index by share price and decides if he…

Read more »

Asian Indian male white collar worker on wheelchair having video conference with his business partners
Investing Articles

With trading suspended, where could the Eurasia Mining (LON:EUA) share price go next?

This morning, the EUA share price was suspended pending an announcement - so could improving sales send the share price…

Read more »

Asian Indian male white collar worker on wheelchair having video conference with his business partners
Investing Articles

Are the FTSE 100’s top income stocks a bargain?

The FTSE 100 is renowned for its value and dividend stocks. So, are the index's top income stocks worth a…

Read more »

Compass pointing towards 'best price'
Investing Articles

Scottish Mortgage shares have slumped 40%. Time to buy now?

Scottish Mortgage Investment Trust (LON: SMT) shares have rewarded shareholders well in recent years. I'm thinking of buying now they're…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Investing Articles

3 recession stocks I’d buy in a hurry

With the economic outlook getting worse, our writer highlights a trio of recession stocks he would consider buying for his…

Read more »